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Abstract
Background: Recent studies indicated that seeded fibril formation and toxicity of α-synuclein (α-syn) play a main
role in the pathogenesis of certain diseases including Parkinson’s disease (PD), multiple system atrophy, and
dementia with Lewy bodies. Therefore, examination of compounds that abolish the process of seeding is
considered a key step towards therapy of several synucleinopathies.
Methods: Using biophysical, biochemical and cell-culture-based assays, assessment of eleven compounds, extracted
from Chinese medicinal herbs, was performed in this study for their effect on α-syn fibril formation and toxicity
caused by the seeding process.
Results: Salvianolic acid B and dihydromyricetin were the two compounds that strongly inhibited the fibril growth
and neurotoxicity of α-syn. In an in-vitro cell model, these compounds decreased the insoluble phosphorylated α-
syn and aggregation. Also, in primary neuronal cells, these compounds showed a reduction in α-syn aggregates.
Both compounds inhibited the seeded fibril growth with dihydromyricetin having the ability to disaggregate
preformed α-syn fibrils. In order to investigate the inhibitory mechanisms of these two compounds towards fibril
formation, we demonstrated that salvianolic acid B binds predominantly to monomers, while dihydromyricetin
binds to oligomeric species and to a lower extent to monomers. Remarkably, these two compounds stabilized the
soluble non-toxic oligomers lacking β-sheet content after subjecting them to proteinase K digestion.
Conclusions: Eleven compounds were tested but only two showed inhibition of α-syn aggregation, seeded fibril
formation and toxicity in vitro. These findings highlight an essential beginning for development of new molecules
in the field of synucleinopathies treatment.
Keywords: α-Synuclein, Parkinson’s disease, Seeded fibril formation, Amyloid fibrils, Salvianolic acid B,
Dihydromyricetin
Background
Parkinson’s disease (PD) is considered a late onset, neuro-
degenerative disease known for the gradual loss of midbrain
dopaminergic neurons found in the substantia nigra [1].
Such neuronal loss leads to the depletion of dopamine, in
the brain. Consequently, a neuropathological characteristic
of PD is the formation of an abundant number of inclu-
sions in the cytoplasm of the degenerating dopaminergic
neurons, known as Lewy neurites (LNs) and Lewy bodies
(LBs) [2]. α-Syn protein is the major component of these
inclusions [3]. Intracellular α-syn inclusions are not only
limited to PD, but also considered a remarkable characteris-
tic of other neurodegenerative diseases, including multiple
system atrophy (MSA) and dementia with Lewy bodies
(DLB) which are identified as synucleinopathies [4].
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Animal, genetic and pathological studies have strongly sup-
ported the importance of α-syn aggregation in the patho-
genesis of synucleinopathies [5].
The mechanisms of α-syn aggregation in the brain
remain unknown. On the other hand, fibril formation of
α-syn studied in vitro was shown to be a nucleation-
dependent process [6], followed by a nucleation (lag-
phase), then an elongation (growth-phase) to reach finally
a steady-state phase [6]. α-Syn pathology has been stated
to propagate in the brain [7]. Considering the importance
of cell-to-cell transmission of α-syn aggregates in the
pathogenesis of synucleinopathies, drug development in
this field should focus on inhibitors of the seeded
polymerization of α-syn instead of fibril growth inhibition.
However, identifying ways to block or inhibit the process
of α-syn aggregation has proven to be challenging. Cur-
rently, drug treatments only serve to relieve the symptoms
of synucleinopathies and do not provide therapy [8, 9].
Several trials are currently taking place to provide novel
and effective treatments that target disease modification,
however, the complicated mechanisms of PD and related
synucleinopathies pathogenesis, are considered a big bur-
den toward this approach. Therefore, the goal to max-
imally inhibit seeded fibril formation of α-syn and its
related cell toxicity may be an alternative and feasible ap-
proach for future treatments of PD and related synuclei-
nopathies [10, 11]. Hence, it is important to identify
potent compounds that can interfere with the early stages
of α-syn aggregation and its seeded fibril growth.
Chinese medicinal compounds, also referred as CMCs,
are well known to be utilized for treating various diseases.
These compounds are extracted from different medicinal
herbs. The field of traditional Chinese medicine has used
CMCs as a therapy for many diseases, such as dementia
[8], neurodegenerative disorders [9], cardiovascular dis-
eases [12], and cancer [13], thus emphasizing Chinese
medicine as a reliable source for disease treatment includ-
ing PD. There has been much research to identify the mo-
lecular mechanism behind the activity of certain CMCs
being used in the field of traditional Chinese medicine. In
this specific medicinal area, baicalein that is the major
component of Scutellaria baicalensis, the traditional Chin-
ese medicine, inhibits wild-type [14] and mutant E46K α-
syn [15] fibril growth, and disaggregates preformed fibrils
in vitro [14]. Moreover, baicalein attenuated induced tox-
icity of E46K α-syn in a Parkinson’s disease cell model
[15]. Furthermore, studies showed that a major constitu-
ent of the Chinese herbal medicine turmeric, curcumin,
inhibited β-amyloid peptide aggregation and toxicity [16].
In the following study, we analyzed the effects of differ-
ent CMCs on the oligomerization and fibril formation of
α-syn for detection of possible inhibitors. Eleven CMCs
(Fig. 1), such as gardenia, ginseng, Japanese raisin tree,
Ginkgo biloba, danshen, peony, licorice, and Japanese
arrowroot, extracted from Chinese herbal medicines
(CHMs), were tested by various assays. These compounds
were obtained from Chinese National Institute for the
Control of Pharmaceutical and Biological Products
(Beijing, China). They are above 98% pure and serve as
the standard compound for quality control. Among the 11
examined compounds, two compounds showed significant
inhibition of α-syn fibril formation, interference with
seeded fibril growth, and protection against α-syn-induced
toxicity. These compounds are salvianolic acid B (CMC1)
and dihydromyricetin (CMC7).
Salvianolic acid B is considered the major water-
soluble component of phenolic acids extracted from the
dried root Salvia miltiorrhiza Bunge with a strong anti-
oxidant, anti-inflammatory [17, 18], and a significant
anti-myocardial ischemia effect [19]. It has recently been
reported that salvianolic acid B shows antitumor activity
against breast cancer cells [20] and suspected to have
potential effect on dementia [21]. Moreover, salvianolic
acid B has a high concentration in the liver and a trans-
porter known as OATP1B1 is involved in its hepatic up-
take and clearance [22]. In general, flavonoids are
implicated in plant coloration and stress resistance [23].
Dihydromyricetin is also a flavonoid compound ex-
tracted from Ampelopsis grossedentata. It has strong
antioxidant [24], antibacterial [25], anti-inflammatory,
and neuroprotective effects, eventually improving motor
and cognitive behavior [26]. Additionally, dihydromyri-
cetin is used to treat osteoporosis, asthma and kidney in-
jury [27, 28]. Being a flavonoid that has a role in plant
coloration, dihydromyricetin is found to be a substrate
for leucodelphinidin production, the latter being the pre-
cursor of blue-hued delphinidin [29].
Methods
Expression and purification of recombinant human α-syn
Human wt α-syn was expressed and purified as previ-
ously described [30–32] . E.coli BL21 bacteria (Invitro-
gen) was used for GST-α-syn fusion construct
expression in the pGEX-4 T1 vector (kindly provided by
Dr. Hyangshuk Rhim, the Catholic University College of
Medicine, Seoul, Korea). The supernatant was kept for
purification with affinity chromatography using glutathi-
one sepharose beads (Amersham-Sweden). The GST-α-
syn bound to beads was cleaved by thrombin enzyme
(Sigma-Aldrich, USA). For thrombin removal of solu-
tion, benzamidine sepharose beads (Amersham-Sweden)
were used. After centrifugation, the concentration of the
resulted pure α-syn protein was purified by reverse
phase HPLC, using analytical phenomenex jupiter C4
columns. Protein concentration was estimated by BCA
assay (Pierce-USA) and the homogeneity and purity of
α-syn was then estimated by analytical HPLC and SDS-
PAGE.
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Aggregation of α-syn in vitro
α-syn was aggregated with or without compounds, as de-
scribed elsewhere [31]. Briefly, the stock solutions of
CMCs (10 mM) were prepared in 100% DMSO, α-syn
samples in PBS were aged with or without CMCs at vari-
ous molar ratios (CMC: α-syn molar ratios of 4:1, 2:1
and 1:1) while the final concentration of α-syn was
25 μM and the DMSO percentage in the working solu-
tion was 1%. Incubation of the samples was performed
at 37 °C for 5 days with continuous shaking at 800 rpm
in a Thermomixer (Eppendorf). At each time point,
Thioflavin-T binding assay was done.
Thioflavin-T (Th-T) assay
This assay was utilized to monitor the fibril formation of
α-syn protein. Thioflavin T is known to be a fluorescent
dye that interacts with fibrils having a β-sheet structure;
it exhibits enhanced fluorescence upon binding to amyl-
oid fibrils and is commonly used to monitor amyloid fi-
bril formation. In this study, we used Th-T assay to
monitor the effect of CMCs on α-syn aggregation, and
CMCs inhibition was calculated using Th-T fluorescent
emission maximum shifted to 486 nm. From each sam-
ple 10 μl, by using the daily basis fresh samples, was
added to 40 μl of Th-T (final concentration is 5 μM of
α-syn and 20 μM of Th-T). Using a microplate reader
(Victor X3 2030, Perkin Elmer), fluorescence (450/486
excitation and emission) was measured with 384-well,
black micro-well plate (Nunc, Denmark).
Transmission electron microscopy (TEM)
Five day old frozen samples of α-syn (5 μL), aged alone
or in the presence of CMCs, were added to copper grids
400-mesh (Agar Scientific, UK) as described before [31,
Fig. 1 Chemical structures of eleven naturally derived Chinese medicinal compounds used to test the effect of α-syn fibril formation. These
compounds are designated as CMC 1–11
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33, 34]. The samples were then fixed by adding 5 μl of
0.5% glutaraldehyde, and then stained with 2% uranyl
acetate. Images were viewed using a Philips CM-10
TEM electron microscope.
Immunoblotting
Samples of α-syn (20 ng), incubated in presence or ab-
sence of CMCs, were mixed with 1X non-denaturing
sample buffer (250 mM Tris-HCl, pH 6.8, 30% glycerol,
0.02% bromophenol blue) and then separated on 15% 1
mm SDS-PAGE gels without boiling the samples as de-
scribed before [31]. Nitrocellulose membranes (What-
man Gmbh-Germany) were used to transfer protein
samples at 90 V for 80 min. The primary mouse mono-
clonal anti-α-syn (211) antibody that recognizes human
α-syn (121–125) (Santa Cruz Biotechnology, USA) was
used to probe the membranes for overnight at 4 °C. This
antibody can recognize both monomeric and aggregated
α-syn equally as has been described before [34–36].
Congo red binding assay
Samples of α-syn (5 μL), aged alone or with CMCs, at
different molar ratios, (using the frozen samples from
the fifth day of incubation day 5), were mixed with
20 μM of Congo red prepared in PBS and filtered
through a 0.45 μM filter. The spectrum of the UV ab-
sorbance (400–600 nm) was measured using 10mm
quartz cuvette by DU 800 spectrophotometer.
Tissue culture of BE(2)-M17 human neuroblastoma cells
These cells were grown in Dulbecco’s MEM/Nutrient
Mix F-12 (1:1) (Gibco BRL, Rockville, MD) supple-
mented by 15% fetal bovine serum and 1% penicillin-
streptomycin (Sigma-Aldrich). They were incubated at
37 °C in a 5% CO2/95% air humidified incubator to
maintain their growth.
Measurement of cell viability
A cell density of 15,000 per well, were plated in a 96-
well plate in DMEM medium. The cells were cultured
for 24 h before replacing the media with 200 μl of OPTI-
MEM (Gibco-USA) serum-free medium containing aged
α-syn solutions, with or without CMCs. The cells were
then incubated for 48 h (37 °C, 5% CO2). To conduct the
MTT assay, 20 μl per well of MTT (3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
(Sigma-Aldrich, USA), with a concentration of 6 mg/ml
in PBS, was added to the cells, followed by 4.5 h incuba-
tion at 37 °C. The medium was then discarded carefully,
and the cells were then lysed by incubating at 37 °C
overnight in 100 μl of lysis buffer (15% SDS, 50% N,N-
dimethylformamide, pH 4.7). Absorbance at 590 nm was
measured by the microplate reader victor X3 (Perkin
Elmer).
Seeding polymerization assay
As described previously, monomeric α-syn aggregation, with
or without seeding, was conducted [37]. Sonication was per-
formed on α-syn fibrils to obtain short fibrils (seeds). Briefly,
2 μM of seeds were added to 100 μM monomeric α-syn and
incubated in the presence or absence of 10 μM or 50 μM of
CMC1 and CMC7 at 37 °C for 6 h with continuous shaking.
The fibril formation in α-syn samples were monitored by
Th-T binding assay as described above.
α-Syn disaggregation assay
As described above, α-syn was aggregated at a concen-
tration of 25 μM. The preformed α-syn aggregates were
incubated alone or with CMC1 and CMC7 at molar ra-
tios of CMC: α-syn 6:1, 4:1 and 2:1. The samples of α-
syn and CMC1/CMC7 were then incubated for 48 h at
37 °C with continuous mixing at 800 rpm. The fibril con-
tent was measured by Th-T assay at regular time points.
Proteinase K (PK) digestion
α-Syn (25 μM), aged alone or in the presence of CMC1,
CMC7, CMC10 and CMC11 at molar ratio 1:1 were sub-
jected to PK digestion (2.5 μg/ml) by incubation for 15
min at 37 °C with PK (Sigma-Aldrich, USA). To stop the
digestion reaction, 2x sample loading buffer (250mM
Tris-HCl, pH 6.8, 30% glycerol, 0.02% bromophenol blue,
8% SDS, 5% beta-mercaptoethanol) was added, followed
by 10min heating at 95 °C. The samples were then sepa-
rated by 15% SDS-PAGE gels followed by silver staining.
Immunocytochemistry staining
Coverslips in 24-well plate were used to grow BE(2)M17
cells expressing wt α-syn for 24 h. After washing twice
with PBS, the cells were fixed using 4% paraformalde-
hyde (15 min, room temperature). The cells were then
permeabilized with PBS-1% triton for 10 min at room
temperature after washing twice with PBS. To minimize
background, 5% normal goat serum in 1% triton was
used for blocking (1 h at room temperature). The anti
human α-syn Ab (211) was incubated with the cells for
3 h at room temperature. The cells were then incubated
with goat anti-mouse secondary Ab conjugated with
FITC (Sigma) for 1 h at room temperature. Afterwards,
the cells were washed three times and the nuclear stain
DAPI was used to stain the nucleus and inverted Axio-
vert 40 CFL fluorescence microscope (Carl Zeiss),
equipped with AxioCam HRc (Carl Zeiss) using the 63x
oil objective was used to take the images.
Size exclusion chromatography (SEC) for separating α-syn
oligomers and monomers
Superdex 200 column was used for the SEC using an
AKTA FPLC system (GE Healthcare-Sweden), to separ-
ate the species generated after the aggregation of α-syn
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(100 μM) with CMC1 and CMC7 (CMC: α-syn molar ra-
tio of 4:1). At day 5 of the aggregation process, the sam-
ple was centrifuged for 45 min at 14,000 x g at 4 °C
generating soluble and insoluble material. Before inject-
ing 80% of the generated supernatant (soluble material),
running buffer (1x PBS, pH 7.4) was used to equilibrate
the column. The elution of α-syn at flow rate of 0.1 ml/
min, was monitored at three different wavelengths (215
nm, 254 nm, and 280 nm). Monomeric α-syn elution
time was determined by co-injecting with molecular
weight standards (ferritin 440 kDa, aldolase 171 kDa, al-
bumin 68 kDa and chymotrypsinogen A 25 kDa) into the
column and eluted at the same conditions mentioned
above. Sample P1 represents the fractions eluting be-
tween 7 and 8ml CV, sample P2 represents the fractions
eluting between 12 and 14ml CV, whereas the fractions
eluting in the 14–16 ml CV were combined and labeled
as monomers (sample P3). Western blotting and TEM
were used to characterize the P1, P2 and P3 fractions.
UV scanning
Concentration of oligomeric and monomeric fractions of
SEC (P1, P2 and P3) samples was done using a speed vac
(CentriVap, Labconco). After estimating the protein con-
centration by BCA assay, UV spectrum 200–600 nm was
measured in a spectrophotometer (DU-800, Beckman-
Coulter).
NMR studies
NMR experiments were done as reported elsewhere [31].
Purified recombinant α-syn (15N-labeled) was obtained
as previously described [38, 39]. To test CMC1, the pro-
tein was re-suspended in buffer at pH 6.5 and for
CMC7, it was re-suspended in PBS pH of 6.7. At a
200 μM α-syn concentration, two-dimensional 1H-15 N
HSQC spectra were acquired in the absence of CMC1
and CMC7 and in the presence of increasing stoichiom-
etries of α-syn: CMC1 or α-syn: CMC7 of 1:0, 1:1, 1:2, 1:
4, 1:6, 1:10, and 1:20. At a sample temperature of 10 °C,
the data were using either a Bruker 800MHz spectrom-
eter equipped with a microprobe or a Bruker 900MHz
spectrometer equipped with a cold probe. Analyzing
changes in chemical shifts and/or changes in resonance
intensity with increasing concentrations of the com-
pounds was used to assay the binding.
Tissue culture of HEK 293 human embryonic kidney cells
These cells were grown in Dulbecco’s MEM- high glu-
cose (Gibco BRL, Rockville, MD) supplemented by 15%
fetal bovine serum (Gibco BRL, Rockville, MD) and 1%
penicillin-streptomycin (Gibco BRL, Rockville, MD) and
incubated at 37 °C in a 5% CO2/95% air humidified incu-
bator. After plating HEK cells overnight in 6-well plates,
cells were transfected with 2 μg of wt α-syn plasmid
DNA (kindly provided by Dr. Denis Selkoe, Harvard
University, USA) by lipofectamine 3000 reagent (Invitro-
gen, Waltham, MA). One group of α-syn expressing
HEK cells was similarly transfected again with 4 μg of α-
syn seeds the following day and then incubated with
compounds (CMC1, CMC7, and CMC10) in OptiMEM
(Gibco BRL, Rockville, MD) for 48 h at a seeds: com-
pound molar ratio of 1:5 and 1:20. The other group of
cells were transfected with both compounds and seeds
at molar ratio of 1:5 and 1:20 by lipofectamine 3000 after
1 h of incubation at 37 °C and shaking at 800 RPM.
HEK cells were lysed, 48 h post transfection, initially
with 1% Trition X-100 in 50mM Tris, 150mM NaCl (pH
7.6) containing protease and phosphatase inhibitors to ob-
tain soluble fractions. The pellet was further lysed with 1%
SDS in 50mM Tris, 150mM NaCl (pH 7.6) with complete
inhibitors to attain insoluble fractions. Protein concentra-
tion was determined by BCA protein assay (Pierce) prior
to analysis on 12% SDS-PAGE and immunoprobing with
certain antibodies. These include monoclonal antibodies
against rabbit phospho S129 alpha-synuclein (AB51253)
(Abcam, Cambridge, MA) and mouse alpha-synuclein
Syn1 (610786) (BD Biosciences, San Jose, CA), in addition
to antibodies against β-Actin (C4) (Sc-47,778) (Santa Cruz
Biotechnology, Dallas, TX) to normalize for the amount of
proteins. Blots were later incubated with horseradish per-
oxidase conjugated with anti-rabbit and anti-mouse IgG
(Jackson ImmunoResearch, West Grove, PA), and proteins
were detected with LiCOR system.
Primary neuronal cultures
Primary cortical neurons were prepared from mice (em-
bryonic day 16) as previously described [40]. Cultures at
6 DIV were either treated with seeds (0.4 μg/0.1 × 106
cells) and compounds (CMC 1, 7, 10 at 1:5 and 1:20 ra-
tio) for 72 h. In pre-treatment experiments, cells were
treated initially with compounds for 24 h and seeds were
then added for an additional 72 h. Following mild trypsi-
nization with 0.05% Trypsin-EDTA for 10min to re-
move the excess of unbound material, cells were washed
with PBS and lysed in STET lysis buffer (50 mM Tris
(pH 7.6), 150 mM NaCl, 1% Triton-X, 2 mM EDTA).
Protease and phosphatase inhibitors were added. Lysates
were then centrifuged at 16,000 g for 40 min at 4 °C. Se-
quentially the pellet was resuspended in 1% RIPA buffer,
sonicated and re-centrifuged. Protein concentration was
estimated by Bradford assay.
Statistical analysis
All experiments were performed in triplicates. Results
shown are mean ± standard deviation (SD). Deviations
are from the average of 3 triplicates. Statistical analysis
for MTT cell viability analysis made using GraphPad
software (nonparametric two-tailed unpaired t-test with,
Ardah et al. BMC Complementary Medicine and Therapies           (2020) 20:73 Page 5 of 21
95% confidence intervals) with asterisks representing dif-
ferences being significant. ***, p < 0.001; **, p < 0.01; *,
p < 0.05. For immunoblotting, band density represent the
amount of the monomeric α-syn were quantitated using
imageJ software.
Results
α-syn fibril formation is inhibited by salvianolic acid B
and dihydromyricetin
To determine whether certain CMCs inhibit α-syn fibril
formation, we screened a small library of eleven CMCs
extracted from different Chinese herbal medicines (Fig.
1) for their effect. Fibril content formation was first
assessed by Thioflavin T assay (Th-T) (Fig. 2a), where
25 μM of α-syn protein was incubated with or without
the corresponding CMC compound in different molar
ratios (CMC: α-syn; 4:1, 2:1, and 1:1). After continuous
shaking for 5 days at 37 °C, the Th-T fluorescence emis-
sion was evaluated every day.
A noticeable decrease in Th-T fluorescence emission was
observed with two compounds, salvianolic acid B (CMC1)
(Fig. 2a; left upper section) and dihydromyricetin (CMC7)
(Fig. 2a; right upper section), as compared to α-syn alone,
indicating a reduction in the amount of α-syn fibrils.
Although both compounds showed an inhibitory effect
on fibril formation, CMC1 effect was more potent than
that of CMC7. CMC1 at higher concentrations (50 and
100 μM) showed complete inhibitory effect especially on
day three after incubation. Following incubation for 5
days, CMC1 (100 μM) inhibited α-syn fibril formation to-
tally, on the other hand, at 50 μM, only 80% was abolished.
Even at a lower concentration of CMC1 (25 μM), this in-
hibition was almost 35% after incubating for 5 days (Fig.
2a left upper panel). On the other hand and after incubat-
ing for 5 days, CMC7 at 100 and 50 μM, had 80 and 40%
inhibition on α-syn fibril formation respectively, whereas,
at 25 μM, the inhibitory effect was only ~ 25% (Fig. 2a; left
upper panel). These results indicate that salvianolic acid B
and dihydromyricetin, had a concentration dependent ef-
fect on α-syn fibril formation, with CMC1 being about 10
times more potent than CMC7.
On the contrary, ammonium glycyrrhizinate, puerarin,
sinomenine, paeoniflorin, gamma-schisandrin, magnolol,
honokiol, and bilobalide also known as CMC2, CMC3,
CMC4, CMC5, CMC6, CMC8, CMC9, and CMC11 re-
spectively (Fig. 2a, right lower panel and Additional file
1) presented no significant effect regarding α-syn fibril
formation. They had comparable outcome compared to
the control (α-syn aged alone) (Table 1); this was illus-
trated by Th-T fluorescence results. Interestingly, geni-
poside or CMC10 slightly stimulated fibril formation
(Fig. 2a, left lower panel). Therefore, we choose to use
CMC10 (slight activator) and CMC11 (a non-inhibitor)
as controls for our subsequent experiments.
Congo Red (CR) binding assay was performed to further
characterize the capability of CMC1 and CMC7 to stop α-
syn fibril formation. The dye, CR has high affinity to amyl-
oid fibrils, where upon its binding, allows the absorbance
maximum of CR to shift from 490 to 540 nm [41]. α-Syn
samples incubated in the absence of CMCs (aged α-syn)
showed a pronounced shift of CR absorption maximum
(Fig. 2b), although this shift was absent in aged α-syn sam-
ples treated with CMC1 (Fig. 2b; left upper panel) or
CMC7 (Fig. 2b; right upper panel), which showed similar
absorbance wavelengths as those observed with mono-
meric α-syn. The CR absorption maximum measured in
α-syn samples with salvianolic acid B and dihydromyrice-
tin (all concentrations) showed a slight shift without ex-
ceeding the wavelength of 495 nm (Fig. 2b, upper panels),
demonstrating that the following compounds inhibit
amyloid fibril formation. Conversely, the rest of other
tested CMCs shift CR absorption maximum similar to
that observed with aged α-syn alone, which confirm their
inability to inhibit the fibril formation (Fig. 2b, lower
panels and Additional file 2).
It is well known that α-syn aggregates are resistant to Pro-
tein Kinase (PK) digestion, hence, we used this assay to con-
firm the inhibitory effect of CMCs on α-syn fibril formation.
Aggregated samples of only α-syn or with CMC1, CMC7,
CMC10 and CMC11 (molar ratio of 1:1) were subjected to
2.5 μg/ml PK treatment. After digestion, they were analyzed
by 15% SDS-PAGE followed by silver staining. α-Syn aged
with CMC1 or CMC7 was digested easily by PK with similar
digestion pattern of that with the monomeric α-syn (Fig.
2c), whereas samples from CMC10 and CMC11 showed a
comparable resistance to PK digestion as observed with aged
α-syn alone (Fig. 2c). This is possibly due to the presence of
stable cross-β sheet structures in these samples (Fig. 2a, b).
The PK digestion results were also confirmed by nega-
tive staining TEM imaging of aged α-syn with or without
CMC1, CMC7, CMC10, and CMC11 under various
molar ratios (CMC: α-syn, 1:1, 2:1, and 4:1). Under all
tested concentrations of CMC1 and CMC7, fibrils ap-
peared thin, short rod-like, and fragmented. On the con-
trary, aged α-syn alone showed dense meshes of long
fibrils (Fig. 2d). On the other hand, CMC10 and
CMC11, showed minute changes in the morphology of
fibrils, compared to the control, even at higher molar ra-
tio concentrations (Fig. 2d). Furthermore, we analyzed
the effect of CMC1 and CMC7 on the aggregation of α-
syn (CMC: α-syn 4:1) for longer incubation time (15
days), and the samples were collected every 5 days for
Th-T (Fig. 2e) and TEM (Fig. 2f) analysis. As shown in
Fig. 2e and f, even after 15 days of incubation both
CMC1 and CMC7 still have the ability to inhibit α-syn
aggregation in both assays. This data is consistent with
the Th-T and CR results that identify CMC1 and CMC7
as inhibitors of α-syn fibril formation.
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To quantify the amount of aggregated protein, SDS-
PAGE was also carried out for the supernatants solution
collected from centrifuged samples of aged α-syn alone with
or without the eleven CMCs for 5 days (Additional file 3).
The amount of α-syn monomers in the samples co-
incubated with either CMC1 or CMC7 was higher when
compared to other compounds, and similar to the freshly
prepared α-syn solution. Furthermore, we also detected high
Fig. 2 Effect of CMCs on α-syn fibril formation. a and b Fibril content formation analysis. α-syn protein (25 μM) was incubated for 5 days at 37 °C
with continuous shaking in the absence (aged alone) or presence of CMC1, CMC7, CMC10, and CMC11 using different molar ratios (CMC: α-syn at
1:1, 2:1, and 4:1). Fibril content for each sample was then measured using a Thioflavin-T (Th-T) and b Congo red binding assays. Means ±
standard deviations are from triplicates of one experiment. c Silver staining for SDS-PAGE of α-syn monomers, α-syn aged alone or in the
presence of CMC1, CMC7, CMC10 and CMC11 at molar ratio 1:1 after Protein Kinase (PK) digestion. d Negative stain electron microscopy images
showing fibril formation of α-syn aged alone or in the presence of the indicated CMCs (CMC: α-syn molar ratios of 1:1, 2:1, and 4:1). Scale bar,
500 nm. e Th-T binding assay for α-syn aged alone or with CMC1 or CMC7 for 5, 10 and 15 days at a molar ratio of 4:1 (CMC: α-syn). Means ±
standard deviations are from the triplicates of one experiment. f Negative stain electron microscopy images showing fibril formation of α-syn
aged alone or in the presence of CMC1 and CMC7 using molar ratio of 4:1 (CMC: α-syn) for 5, 10 and 15 days. Scale bar, 500 nm
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molecular weight oligomers in all samples except in the
samples co-incubated with either CMC1 or CMC7 (Add-
itional file 3). These results clearly confirm that CMC1 and
CMC7 inhibit the aggregation of α-syn.
α-Syn oligomerization is stabilized by salvianolic acid B
and dihydromyricetin
Assessment of α-syn oligomerization upon CMC treat-
ment was done by immunoblot analysis, where α-syn fresh
aged solutions with or without different molar ratio con-
centrations of CMCs were analyzed. For both controls (α-
syn fibrils and monomers) as well as CMCs, most of
freshly prepared α-syn showed migration at a band of ~
16 KDa that corresponds to monomeric α-syn (Fig. 3).
However, larger oligomers of MW > 250 kDa were inhib-
ited by CMC1 and CMC7, which also inhibited α-syn fibril
formation (Fig. 2), indicated by the disappearance of the
trimeric α-syn species and the generation of more prom-
inent monomeric species of the protein with the highest
molar ratio (4:1) of both compounds (Fig. 3). As shown by
the bands, monomeric, dimeric, and trimeric α-syn were
the most dominant species, while the band indicating tri-
meric α-syn was weak, using the 4:1M ratio of the com-
pounds (Fig. 3a, lane 3).
The remaining of tested compounds had an analogous
effect on α-syn oligomerization as that of fibril formation.
For simplicity reasons, we referred to two compounds:
CMC10 representing those that induce oligomerization,
and CMC11 representing the group of CMCs that does
not affect oligomerization (Fig. 3). In contrast, CMC10
slightly enhances fibril formation and CMC11, which has
no effect (Fig. 2a), showed analogous effect on α-syn
oligomerization (Fig. 3). Indeed, under different concen-
trations of CMC10, oligomerization of α-syn was
enhanced in comparison to control. This was consistent
with the presence of several clear bands matching oligo-
meric species (Fig. 3), whereas the counterpart concentra-
tions of CMC11 showed similar intensity and band
separation to the control (Fig. 3) indicating that CMC11
failed to influence α-syn oligomerization. This was con-
firmed by the detection of the same amount of mono-
meric α-syn species in all concentrations for CMC10 and
CMC11 as well as the α-syn aged alone as compared to a
fresh α-syn sample containing only the monomers (Fig. 3).
This data indicates that CMC1 and CMC7, that inhibit α-
syn fibril formation, stabilized α-syn oligomers rather than
inhibiting oligomerization.
α-Syn-induced cytotoxicity is hindered by salvianolic acid
B and dihydromyricetin
Since α-syn aggregates was previously reported to induce
cell toxicity [42–45], we were interested to determine the ef-
fect of CMCs on α-syn-induced cell toxicity. Aged α-syn
with or without CMC1, CMC7, CMC10 and CMC11 at the
following concentrations 0.5, 1 and 5 μM, were used to treat
BE(2)-M17 human neuroblastoma cells to be examined for
cell viability by MTT assay. At first, cell viability studies
were performed with only CMCs to determine their non-
toxic concentrations (Additional file 4) which were later
combined with aged α-syn. CMCs alone did not induce any
significant toxic effect on the cells at any concentration
tested (Additional file 4), however, aged α-syn decreases cell
viability in a dose-dependent fashion that reaches to 50%
cell death with 5 μM concentration (Fig. 4 a-d). Importantly,
such toxic effect was significantly reversed when α-syn solu-
tion was aged in the presence of CMC1 or CMC7 (Fig. 4a
and b, respectively). Cell viability enhanced significantly with
CMC1 reaching 95% at molar ratios 4:1 and 2:1 (Fig. 4a)
Table 1 The small compounds from Chinese herbal medicines and their effect on fibril formation, oligomerization and toxicity
ID Name Inhibition of fibril formation
(Th-T)a
Inhibition of fibril formation
(CR)b
Inhibition of seeded fibril
formationc
Inhibition of
neurotoxicityd
CMC 1 Salvianolic acid B + + + +++ + + + + + +
CMC2 Ammonium
Glycyrrhizinate
+ + – –
CMC3 Puerarin – – – –
CMC4 Sinomenine + – – +
CMC5 Paeoniflorin + – – –
CMC6 Gamma-Schisandrin – – –
CMC7 Dihydromyricetin + + + +++ + + + + + +
CMC8 Magnolol – – – –
CMC9 Honokiol + – – +
CMC10 Geniposide – – – –
CMC11 Bilobalide ++ + – +
aInhibition of α-syn fibril formation was tested by Th-T assay. bInhibition of α-syn fibril formation was tested by Congo red assay. cInhibition of α-syn seeded fibril
formation was tested by seeding assay. dInhibition of α-syn fibril toxicity toward M17-neuroblastoma cells was tested by MTT assay. (+ + +, very potent; ++,
potent; +, moderate; −, no effect)
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and similarly, CMC7 reduced α-syn toxicity, as potently as
CMC1 (Fig. 4b). On the contrary, no improvement in cell
survival was observed in neuroblastoma cells when treated
with aged α-syn in the presence of CMC10 or CMC11 (Fig.
4c and d). Interestingly, the decrease in Th-T counts at
molar ratios 4:1 and 2:1, proved the inhibitory effect of
CMC1 on fibril formation (Fig. 2a).
To confirm the data observed from MTT assay, we
used BE(2)-M17 (neuroblastoma cells) that were treated
with 5 μM aged α-syn with or without CMCs (1, 7, 10
and 11) at a molar ratio of 4:1 (CMC: α-syn). This was
followed by immunostaining for alpha synuclein. Fluor-
escence microscopy imaging showed untreated cells as
healthy with diffused cytoplasmic α-syn staining (Fig. 4e;
control) whereas cells treated with aged α-syn lost their
neuronal shape and appeared rounded and unhealthy,
with an apparent accumulation of aggregated fibrils at
the cell membranes. Treating cells with aged α-syn and
either CMC1 or CMC7, showed normal cells without
any aggregates on cell membranes (Fig. 4e; aged α-syn
alone). On the other hand, in the presence of CMC10 or
CMC11, treated cells seemed round, and unhealthy with
extracellular, membrane-bound aggregates (Fig. 4e).
This data indicate that CMC1 and CMC7, but not
CMC10 or CMC11, are able to rescue the cells from ag-
gregated α-syn-induced toxicity. These findings are in
agreement with the ability of CMC1 and CMC7 to inhibit
aggregation (Fig. 2) as well as oligomerization (Fig. 3).
Dihydromyricetin disaggregates preformed α-syn amyloid
fibrils
Since both CMC1and CMC7 clearly inhibited α-syn fi-
bril formation, we further examined the possibility of re-
versing this process. Thus, preformed α-syn fibrils
(25 μM) were incubated at 37 °C with the above men-
tioned CMCs at molar ratios of CMC: α-syn 6:1, 4:1,
and 2:1 for 48 h. Fibril content formation was then esti-
mated by measuring the intensity of Th-T fluorescence
emission at different time points (0, 2, 4, 6, 12, 24, and
48 h) (Fig. 5a and b). At 0 h, Th-T counts for α-syn incu-
bated alone or with CMC1 was estimated to be 20,000.
At this time point, Th-T counts were even lower with
CMC7 (Fig. 5a and b). As indicated by the increase in
Th-T counts (Fig. 5a and b), α-syn fibrils incubated
alone continued aggregating with time, on the other
hand, α-syn fibrils incubated with CMC7 significantly
Fig. 3 Effect of CMCs on α-syn oligomerization. a Immunoblot analysis of different species of α-syn (monomeric, dimeric, oligomeric, and
aggregates). Different species of α-syn were detected in samples collected from α-syn aged alone or in the presence of CMC1, CMC7, CMC10 and
CMC11 at CMC: α-syn molar ratios of 1:1, 2:1 and 4:1 for 5 days. F: α-syn fibrils, M: monomeric α-syn, Lane 1, CMC: α-syn 1:1, lane 2, CMC: α-syn
2:1, lane 3, CMC: α-syn 4:1, b Band density representing the amount of monomeric α-syn was quantified for each sample using ImageJ software
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disaggregated with time, as indicated by the decrease in
Th-T counts (Fig. 5b). The disaggregation occurred in a
dose-dependent fashion and reached its maximal levels
(10 fold decrease in Th-T counts as compared to con-
trol) after 48 h with 6:1 M ratio concentration (Fig. 5b).
On the other hand, Th-T measurements were the same
for α-syn incubated alone or with CMC1 (Fig. 5a). This
in turn indicates that the compound failed to disaggre-
gate the preformed α-syn fibrils. Thus only CMC7, but
not CMC1, showed ability to disaggregate preformed α-
syn fibrils by a dose-dependent fashion.
TEM imaging of aged α-syn in presence or absence of
CMC1, CMC7 (CMC: α-syn, 6:1) for 0 and 48 h was fur-
ther used to confirm these results. Typical long fibrils
were observed in α-syn aged alone (Fig. 5c, left panels)
or in the presence of CMC1 (Fig. 5c, middle panels), but
not CMC7 that shows short fragmented rod-like fibrils
(Fig. 5c, right panels). To exclude the possibility that the
species formed from disaggregation of preformed α-syn
fibrils by CMC7 are toxic, BE(2)-M17 cells were treated
with pre-formed aged α-syn either alone or in the pres-
ence of CMC7 and cell viability was determined using
the MTT assay. The percentage of cell viability clearly
showed that those species were not toxic to the cells as
compared to the control untreated cells and to the pre-
formed α-syn fibrils alone (Fig. 5d).
The seeding of α-syn monomers is interfered by
salvianolic acid B and dihydromyricetin
Mechanistically, amyloid fibril formation is formed in a
three step process according to a nucleation-dependent
polymerization model [46, 47]. This process was accelerated
Fig. 4 Effect of CMCs on cell toxicity of α-syn aggregates. a-d MTT cell viability analysis. The viability of BE(2)-M17 human cells treated with either
α-syn aged alone or with a CMC1, b CMC7, c CMC110, and d CMC11 was tested by MTT assay. Cells were treated with the indicated
concentrations of α-syn and CMCs for 48 h prior to the addition of MTT. The results are expressed as percentages of the average of the control
(i.e., untreated cells). Means ± standard deviations are from the average of 3 wells. Statistical analysis was performed using a two-tailed unpaired
t-test. ***, p < 0.001; **, p < 0.01; *, p < 0.05. e Immunocytochemistry against α-syn (green) and DAPI (blue) in BE(2)-M17 cells treated with
aggregated α-syn. The cells were either non-treated or treated for 48 h with 5 μM of α-syn aged alone or in the presence of CMC1, CMC7,
CMC10, and CMC11at a molar ratio of 1:4. Scale bar 30 μm
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by the presence of small aggregates or seeds that bypass the
nucleation phase of amyloid fibrils formation in vitro and
in vivo through a process called seeding [7, 48–50]. Our re-
sults show that CMC1 and CMC7 interfere with the forma-
tion of α-syn fibrils (Fig. 2) and that CMC7, but not CMC1,
disaggregated preformed α-syn fibrils (Fig. 5), therefore it
was in our interest to determine whether these compounds
could affect the α-syn seeding. Sonication of mature α-syn
fibrils formed seeds known as short fibrils. The latter was
added to α-syn monomers to start the aggregation process.
Monomeric α-syn containing seeds (100 μM), at a final
concentration of 2 μM, were incubated either alone or in
combination with two different concentrations (10 or
50 μM) of the eleven CMCs. This combination was exposed
to incubation with continuous shaking at 37 °C for 6 h, and
the intensity of Th-T fluorescence emission was recorded
for each hour.
Acceleration of monomeric α-syn fibril formation was
evident after adding short fibrillary seeds. The formation
of α-syn fibrils after a 6 h incubation was comparable
with 72 h incubation of the protein without seeds (com-
pare Figs. 6a and 2a). Remarkably, 50 μM of CMC1 and
CMC7, significantly inhibited the seeding process (~
90%) at all time points as shown by low Th-T readings
(Fig. 6a and b). At 10 μM concentration, CMC7 showed
an intermediate seeding inhibition of α-syn monomers
that starts 3 h after incubation (Fig. 6b). CMC1 only ex-
hibited a minor inhibition (Fig. 6a). On the other hand,
all the other nine compounds did not show any inhib-
ition even at the higher concentration (Additional file 5).
To confirm this inhibitory effect of CMC1 and CMC7,
TEM imaging was also done on monomeric α-syn con-
taining seeds with or without the compound (50 μM) for
6 h. As shown in Fig. 6c, α-syn alone showed dense long
Fig. 5 Effect of CMC1 and CMC7 on performed α-syn fibrils. a and b Th-T binding assay used to measure the fibril content resulted from the
incubation of aggregated α-syn for the indicated times in the absence or presence of a CMC1 and b CMC7 using different molar ratios (CMC: α-
syn at 6:1, 4:1, and 2:1). The assays were performed in triplicates (Means ± standard deviations are from the average of the triplicates). c Electron
microscopy images of negatively stained samples of aged α-syn incubated alone or in the presence of CMC1 and CMC7 (CMC: α-syn at 6:1) for 0
h (upper panels) or 48 h (lower panels) with continuous shaking at 37 °C. Scale bar, 500 nm. d Cell viability of BE(2)-M17 cells was tested using
MTT assay. Cells were treated for 48 h with pre-formed α-syn fibrils or with the pre-formed fibrils incubated with CMC7 prior to the addition of
MTT. Results are expressed as percentages of the average of the control (i.e., untreated cells). Means ± standard deviations are from the average
of 3 wells
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fibrils (Fig. 6c), whereas in the presence of CMC1 or
CMC7 small fragmented rod-like fibrils were observed.
These structures are similar to those observed with α-
syn alone at 0 h when there was no fibril formation
(Fig. 6c). To further study the seeding process after
CMC1 and CMC7 treatment, 2 μM of the species re-
sulted from incubation CMC1 and CMC7 with α-syn
for 5 days (Fig. 2a), were also tested for their ability to
seed the aggregation of α-syn monomers. As shown in
Fig. 6d, those species failed to seed alpha synuclein ag-
gregation. Collectively, these results suggest that CMC1
and CMC7 are able to interfere with α-syn seeding
process.
Inhibition of α-syn fibril formation by salvianolic acid B
and dihydromyricetin is mediated by binding to
monomeric and oligomeric species respectively and
forming stable oligomers
To determine which species of α-syn interact with
CMCs, 100 μM of monomeric α-syn was aggregated with
CMC1 and CMC7 at 4:1M ratio. Following by 5 day in-
cubation, centrifugation of samples was performed and
Fig. 6 Effect of CMC1 and CMC7 on the seeding of α-syn monomers with fibrils. α-syn monomers (100 μM) were seeded with 2 μM sonicated α-
syn fibrils, which were then incubated in the presence or absence of a CMC1 and b CMC7 at different concentrations (10 and 50 μM) for 6 h with
continuous shaking at 37 °C. The extent of fibril formation was estimated by Th-T binding assay. The assays were performed in triplicate (average
of triplicate measurements ± standard deviations). c Electron microscopy images of negatively stained samples of α-syn incubated with seeds
alone or in the presence of CMC1 or CMC7 in a concentration of 50 μM for the indicated times with continuous shaking at 37 °C. Scale bar, 500
nm. d Th-T binding assay for seeding the aggregation of α-syn monomers by either 2 μM of untreated seeds (wt seeds) or seeds generated from
the incubation of CMC1 or CMC7 with α-syn fibrils for 5 days at a molar ratio of 4:1
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the corresponding supernatant was injected in a super-
dex 200 SE column. Monomeric α-syn elution volume
was determined by molecular weight standard (Add-
itional file 8) and as expected this species was eluted in a
peak (P3) that corresponds to elution volume of 14–16
ml (Fig. 7a, b upper panels and Additional file 8). In con-
trast, peaks corresponding to elution volume ~ 7–8 (P1)
and 12–14 ml (P2) represent the oligomeric α-syn spe-
cies (Fig. 7a and b, upper panels). Peak fractions corre-
sponding to each species were separately pooled
together (Fig. 7a and b, upper panels), concentrated
using a speed vac, yielding a final volume of 300 μl for
each peak, and then the concentration of α-syn species
that corresponds to each peak was detected. The con-
centrations were (P1 = 45 μg/ml, P2 = 300 μg/ml, P3 =
700 μg/ml) and (P1 = 78 μg/ml, P2 = 410 μg/ml, P3 =
689 μg/ml) for CMC1 and CMC7, respectively. Before
loading the sample into the gel filtration column, the
samples were centrifuged for 10 min/14,000 rpm, and
only the supernatant was injected to assure that only sol-
uble aggregates were loaded into the column. α-Syn spe-
cies in these samples were analyzed by western blotting
Fig. 7 CMC1 and CMC7 binding activity to α-syn monomers and oligomers. a and b Upper panels: Gel filtration profiles of 100 μM α-syn sample
incubated with a CMC1 and b CMC7 at 4:1 M ratio (CMC1: α-syn) for 5 days as described in Materials and Methods using Superdex 200 SE
column. Peak 1 (P1) and Peak 2 (P2) represent the oligomers species while Peak 3 (P3) represents the monomeric species. The elution was
monitored at absorbance wavelengths of A215, A254 and A280. The inset shows immunoblot analysis of different α-syn species (monomers, dimers,
and oligomers) separated from the pooled fractions of P1, P2 and P3. Lower panels: Electron microscopy images showing α-syn species resulted
from the indicated peaks. c UV absorbance of α-syn P1, P2 and P3 samples collected from the gel filtration chromatography resulted from the
incubation of α-syn with CMC1 (left panel) or CMC7 (right panel). d UV absorbance of CMC1 alone (left panel) and CMC7 (right panel). Samples
were placed in a10 mm quartz cuvette and the UV absorbance spectra were recorded from 200 nm to 600 nm
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(Fig. 7a and b, insets) and TEM, (Fig. 7a and b, lower
panels). Western blotting showed that the oligomer spe-
cies formed upon incubation of α-syn with both CMC1
(Fig. 7a, inset) and CMC7 (Fig. 7b, inset) are stable
under these conditions. In accordance with the immuno-
blotting results, negative staining TEM imaging of the
same samples pointed the presence of different species
of oligomers in P1 and P2, but not in P3 that contains
the monomers (Fig. 7a and b, lower panels). To identify
the incorporated CMC1 and CMC7 in P1, P2 and P3,
we exploited the property of both compounds to pro-
duce UV absorbance spectra with three notable peaks
(Fig. 7c and d, upper panels) as well as with each com-
pound alone (Fig. 7c and d, lower panels). CMC1 was
mainly detected in the monomeric P3, while CMC7 lies
within the P2 (oligomeric species) range, with fewer
amounts in P3 (Fig. 7c). Collectively the data indicates
that CMC1 and CMC7 may possibly inhibit α-syn fibril
formation through their binding to the monomeric and
oligomeric α-syn species, respectively.
To further assess whether CMC1 and CMC7 interacts
with monomeric α-syn, we monitored the effect of adding
an excess of each compound into a solution containing
monomeric α-syn using two-dimensional NMR spectros-
copy, which gives signals covering the entire amino acid se-
quence of α-syn. Upon addition of 4mM CMC1 to
samples of 0.2mM monomeric α-syn, we observed signifi-
cant chemical shift and resonance intensity changes
(Fig. 8a), confirming that CMC1 interacts significantly with
monomeric α-syn. In contrast, addition of the same con-
centration of CMC7 to equivalent samples of monomeric
α-syn resulted in no significant chemical shift or resonance
intensity changes (Fig. 8d). To better characterize the effects
of the compounds, we performed NMR-monitored titra-
tions using a range of compound concentrations from 0.2
to 4mM. We observed a dose-response effect on both
chemical shifts and resonance intensities upon titrating in
CMC1 (Fig. 8b and c), confirming the ability of this com-
pound to interact with monomeric α-syn. Interestingly, the
interaction region on α-syn was quite extensive, encom-
passing approximately the N-terminal 60 residues of the
protein. Somewhat similar behavior has previously been ob-
served for the binding of α-syn to the amyloid-staining
compound Congo Red, which segregates monomeric α-syn
into micelles of varying sizes [51]. Fitting the resonance in-
tensity titration data using either individual resonance in
this region or integrated resonance intensities over the N-
terminal ~ 30 or ~ 60 residues (data not shown) yielded
binding constant estimates ranging from 1.4 to 1.7mM.
Salvianolic acid B and dihydromyricetin affect the seeding
dependent aggregation of α-syn in cells
Effect of CMCs (CMC1, CMC7 and CMC10) on seeding
dependent aggregation and the formation of insoluble
phosphorylated α-syn at Ser 129 (pS129-α-syn) was
studied in an in-vitro cell model of α-syn expressing
HEK cells. Insoluble pS129-α-syn was induced after a
consecutive transfection of 2 μg wt α-syn plasmid DNA
and 4 μg α-syn seeds. The results indicate that the two
compounds, salvianolic acid B (CMC1) and dihydromyr-
icetin (CMC7), decreased insoluble pS129-α-syn in a
concentration dependent manner: 1:20 > 1:5M ratio of
the insoluble fractions compared to the group of cells
that were transfected with both wt-α-syn plasmid DNA
and α-syn seeds (Fig. 9a). Additionally, these two com-
pounds reduced the seeding dependent aggregation of α-
syn in the insoluble fractions to a higher extent in 1:20
(seeds: CMC) molar ratio group of HEK cells that were
transfected with both seeds and CMC by lipofectamine
3000 after their incubation at 37 °C for 1 h. This pro-
vides evidence that CMC1 and CMC7 both have an in-
hibitory effect on the seeding effect in insoluble
fractions. On the other hand, soluble fractions did not
reflect any differences between groups treated with ei-
ther CMC1 or CMC7 (Fig. 9a). With regards to CMC10,
there were no evident changes in both soluble and insol-
uble fractions between the different groups indicating its
lack of any inhibitory effect on seeding dependent aggre-
gation of α-syn and consequential formation of insoluble
pS129-α-syn (Fig. 9).
The impact of the compounds on α-syn aggregation
was further examined in another cell model using pri-
mary neuronal cultures treated with seeds. After trypsi-
nization, lysates were sequentially fractioned using
Triton-X, and RIPA. α-Syn species were detected in the
insoluble fractions by immunoblotting with the α-syn
antibody C20. As shown in Additional file 6, insoluble
α-syn species were increased after treating primary cor-
tical neurons with α-syn seeds. However, neurons
treated with CMC1 and CMC7 showed a clear reduction
of α-syn aggregates associated with the cells. Similar re-
sults were obtained following pre-treatment of neurons
with the compounds before addition of the seeds. How-
ever, CMC10 had no effect on α-syn aggregation in any
condition tested. Interestingly, we did not observe any
changes in pS129-α-syn species in the neuronal cells fol-
lowing treatment with the compounds as verified by im-
munoblotting with the α-syn (pSer129) specific antibody
(Additional file 6).
Discussion
Due to the increased frequency of PD in elderly
people, the disease is designated as a progressive neu-
rodegenerative disorder, where its incidence is rising
sharply worldwide and is expected to double by the
year 2030 [52]. Currently, symptomatic treatments for
PD are only available, which do not only have a mod-
erate relief effect, but also are associated with several
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side effects. Therefore, the development of novel,
more effective and safe treatments for PD becomes a
real must. Several etiological factors have been linked
to PD pathology [53], however, several research stud-
ies convincingly showed that the misfolding and ag-
gregation of the α-syn protein has a critical role in
PD pathogenesis and other disorders [53–55]. More
recent studies indicated the important role of the
seeded fibril formation and toxicity of α-syn in the
pathogenesis of PD and related synucleinopathies.
Consequently, the seeding process becomes a relevant
target for the development and design of novel mole-
cules that inhibit this process and its components [10,
30, 31, 56–58]. In recent years, various CMCs isolated
from CHMs have emerged as potent amyloid aggre-
gating inhibitors [14–16], indicating that screening
Fig. 8 Analysis of CMC1 and CMC7 binding to monomeric α-syn by NMR spectroscopy. a Proton-nitrogen correlation (HSQC) spectra b averaged
NMR chemical shift perturbation of 1H/15N resonances, and c Residue-specific NMR signal intensity ratios of α-syn in the absence and presence of
increasing stoichiometries of CMC1 (CMC1: α-syn of 0:1, 1:1, 2:1, 4:1, 6:1, 10:1, and 20:1). d Proton-nitrogen correlation (HSQC) spectra and e
Residue-specific NMR signal intensity ratios of α-syn in the absence and presence of increasing stoichiometries of CMC7 (CMC7: α-syn of 0:1, 1:1,
2:1, 4:1, 6:1, and 10:1)
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CMCs is a good strategy for identifying potential in-
hibitors of α-syn aggregation.
In the present study, eleven CMCs were screened for
their effect on early (soluble oligomers) and late (fibrils)
aggregate formation of α-syn. Salvianolic acid B (CMC1)
and dihydromyricetin (CMC7) were the two compounds
being most potent for inhibiting α-syn seeded fibril for-
mation and related cell toxicity. Moreover, these two
compounds have shown to be nontoxic having no effect
on cell viability (Additional file 7). CMC1 is known to be
extracted from Radix Salvia miltiorrhiza (Danshen) [59].
Danshen has been used for centuries in the field of trad-
itional Chinese medicine as therapy for cardiovascular
disorders. Given its polyphenolic structure, salvianolic
acid B is characterized by its anti-oxidative ability [60,
61]. Dihydromyricetin (CMC7), a flavonoid known to be
a hangover cure, is extracted from the Japanese raisin
tree (Hovenia dulcis) [62].
For the first time, our findings present evidence that sal-
vianolic acid B (CMC1) and dihydromyricetin (CMC7) dis-
rupt α-syn fibril formation in vitro, and exhibited a
concentration-dependent inhibition. Moreover, both com-
pounds had a protective role in neuroblastoma cells against
α-syn toxicity in vitro, showing a clear increase in cell via-
bility. Electron microscopy studies conducted on aged α-
syn solution with CMC1 and CMC7 revealed this protein
as fibrils with a small, sheared, rod-like morphology. It was
also found to be non-toxic and unable to elongate.
The following findings are consistent with previous
studies that defined salvianolic acid B as anti-
fibrillogenic and neuroprotective [63]. Moreover, sal-
vianolic acid B has been previously noted for its abil-
ity to inhibit fibril formation of amyloidogenic
compounds [β-amyloid (Aβ), human islet amyloid
polypeptide (hIAPP)] and to protect cells against tox-
icity [64]. Other than blocking the fibril formation of
Fig. 9 Effects of CMC1, CMC7, and CMC10 on insoluble pS129-α-syn and aggregation. Insoluble pS129 and aggregation of α-syn were assessed in
10 μg and 15 μg of insoluble a and soluble b proteins from cell lysates of untransfected (control) and transfected HEK cells by immunoblotting
proteins using antibodies specific to pS129-α-syn and total α-syn (Syn1). While one group of wt α-syn transfected HEK cells were simultaneously
transfected with seeds and CMC at different molar ratios (1:5 and 1:20) after an incubation at 37 °C for 1 h, the other group was transfected with
seeds to be followed by CMC treatment at different molar ratios (1:5 and 1:20) in OptiMEM for 48 h. Recombinant pS129-α-syn (rpS129-α-syn) and
recombinant α-syn (r-α-syn) proteins were loaded (50 ng) as positive controls. Re-immunoblotting with β-actin antibody was performed to
normalize the amount of loaded proteins
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Aβ [64], salvianolic acid B also disaggregates pre-
formed Aβ fibrils [65]. Moreover, this compound re-
vealed neurotrophic properties, protecting cells from
toxic effects of Aβ42 [65] and Aβ25–35 [64–66]. Im-
portantly, recent in vivo studies confirmed the neuro-
trophic properties of salvianolic acid B [67, 68].
Another study also showed that salvianolic acid B in-
hibits hIAPP formation of fibrils, disaggregates pre-
formed hIAPP fibrils and protects pancreatic INS-1
cells from the toxic effects of hIAPP [69].
Many phenolic compounds, including baicalein [14, 70],
epigallocatechin gallate (EGCG) [71], rosmarinic acid [51,
70], tannic acid [70, 72], myricetin [70, 72], gallic acid [34]
and ginsenoside Rb1 [31], have been earlier shown to inhibit
α-syn fibril formation, which is consistent with our results.
Given the evidence that polyphenolic compounds inhibit
the elongation phase of amyloid aggregation [14, 73] and
the fact that both salvianolic acid B (CMC1) and dihydro-
myricetin (CMC7) are phenolic compounds with four and
two phenyl rings in their structures, respectively, clarifies
the reason CMC1 and CMC7 inhibited α-syn fibril forma-
tion (Fig. 2a and b). Additionally, these two compounds gen-
erated small aggregates with a sheared appearance (Fig. 2d),
and this inhibitory effect was still detectable even after 15
days of incubation of CMC1 and CMC7 with α-syn (Fig. 2e
and f). Mechanistically, inhibition of α-syn aggregation by
phenolic compounds is thought to be intermediated by in-
teractions between the phenolic compounds and the aro-
matic residues of the amyloids. This eventually directs the
former towards the amyloidogenic core; therefore, interfer-
ing with the π-stacking of the rings of the aromatic residues
that promote amyloid aggregation [74]. Moreover, the at-
tached hydroxyl moieties to the phenyl rings of the phenolic
compounds have an important role in the inhibition of the
β-sheet structure through competitive hydrogen bonding
[74]. Of interest, CMC7 disaggregated preformed fibrils of
α-syn (Fig. 5b) and generated non-toxic species to M17 cells
(Fig. 5d), on the other hand CMC1 did not (Fig. 5a). Add-
itionally, CMC1 and CMC7 were reported to inhibit the
seeded fibril formation of α-syn monomers, with CMC7
having the ability to inhibit at both tested concentrations
(Fig. 6b and c), while CMC1 showed complete inhibition
only at high concentration (50 μM) and a less inhibitory ef-
fect at 10 μM (Fig. 6a). This was evident in the in-vitro cell
model of HEK cells where α-syn phosphorylation and aggre-
gation were induced by transfection of plasmid α-syn DNA
and seeds. Upon treatment of these cells with CMC1 and
CMC7 at the molar ratio of seeds: CMC 1:20, these two
compounds minimized the seeding effect, indicating a piv-
otal role in blocking the seeded aggregation of α-syn (Fig. 9).
In contrast, all other CMCs tested failed to block seeding at
any concentration (Fig. 6a). This was further confirmed in
primary neuronal cultures treated with the seeds in the pres-
ence of the two compounds. To this end, CMC1 and
CMC7 treatments produced a clear reduction of the insol-
uble α-syn species associated with the neurons following
treatment with seeds. Surprisingly, the compounds failed to
produce a similar reduction in the phosphorylated α-syn
species in neuronal cells. It is possible that treatments with
seeds longer than 72 h are needed to increase phopshoryla-
tion of α-syn in this model. In this study, we also showed
that salvianolic acid B (CMC1) has the ability to bind to
monomers (Figs. 7c; 8a-c), while dihydromyricetin (CMC7)
was found to bind mainly to oligomers and with a lower af-
finity to monomers (Figs. 7c; 8d and e). This in turn may
provide a starting point to investigate the mechanisms of ac-
tion of these two compounds in inhibiting the fibril forma-
tion of α-syn. Interestingly, the binding behavior of
salvianolic acid B is similar to that previously observed for
CR, which segregates α-syn into micelles of varying sizes
[75], suggesting that salvianolic acid B may operate via a
similar mechanism. Indeed, the relatively high concentra-
tions of salvianolic acid B required for the interaction may
reflect a requirement for micelle formation prior to binding.
This could also explain the extensive region of interaction,
encompassing much of the N-terminal domain of α-syn.
This region is known to mediate the interactions of α-syn
with lipid membranes [38, 39], and may therefore be prone
to interacting with extended surfaces formed by membranes
or micellar forms of lipids, detergents and other amphiphiles
[51]. Characterizing the detailed molecular interactions of
α-syn with salvianolic acid B in greater detail will require
further future work as both are involved in the binding of
an extensive region of the protein, residues ~ 1–60, likely to
a micellar surface, rather than interactions of individual resi-
dues with individual molecules of the compound.
Amyloid fibrils are insoluble, highly organized, strong
fibers that are formed by a major number of proteins.
These fibers are known to be resistant to degradation
and are linked to several diseases such as PD. Aged α-
syn form amyloid fibrils, that are rich in β-sheet content,
upon binding to the membrance of the cell, cause alter-
ations within the cell. These changes start with mem-
brane permeabilization that leads to a disruption in
calcium homeostasis, which in turn can cause cell tox-
icity [76–78]. Indeed, our fluorescence results, in cul-
tured BE(2)-M17 that were exposed to aggregated α-syn
alone, suggest the localization of α-syn aggregates to the
cell plasma membrane (Fig. 4e). It should be noted that
those cells were rounded, unhealthy, and lose their char-
acteristic neuronal shape identity (Fig. 4e). Our fluores-
cence results identify CMC1 and CMC7, which prevent
α-syn fibril formation, as rescuers of α-syn aggregates
cell toxicity. These two compounds interfered with the
toxic effect of these aggregates as seen by the absence of
α-syn accumulation at the cell membrane as well as the
apparent healthy appearance of the cells (Fig. 4e). In
contrast, CMC10 and CMC11 that are considered poor
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inhibitors of α-syn fibril formation, resulted in the for-
mation of membrane-bound aggregates, with the cells
being unhealthy and rounded (Fig. 4e). In agreement
with this, our MTT assay data also provided strong evi-
dence that CMC1 and 7 (Fig. 4a and b) but not CMC10
and 11 block α-syn aggregate cytotoxicity. It is also in-
teresting to point out that our data showed that CMC1
and CMC7 are capable of inhibiting α-syn fibril forma-
tion and stabilizes soluble, non-toxic oligomers without
a β-sheet content (Fig. 2). This drove us to hypothesize
the role of CMC1 and CMC7 and their potential neuro-
protective role through their natural aptitude to interfere
with the generation of α-syn toxic fibrils that contain β-
sheet structures thus preventing plasma membrane dis-
ruption in neuroblastoma cells.
According to our NMR and SEC combined with
UV spectroscopy results, CMC1 causes α-syn inhib-
ition of fibril formation through its interaction with
monomeric α-syn, and stabilizing the structure of sol-
uble oligomeric α-syn without any β-sheet content
(Figs. 7d, 2a-d and Additional file 3), causing it to be
non-toxic (Fig. 4a). Whereas, CMC7 was found to
bind to the oligomeric species and further stabilize
the structure of soluble oligomeric α-syn without β-
sheet content. However, other techniques will have to
be performed to support and confirm whether the
secondary structure was completely depleted or not.
It is possible that a very weak interaction between
CMC7 and monomers occurs, but may have been
missed by NMR, as was the case in the analysis of
Hsp70 binding [79, 80]. After further analysis of the
size exclusion findings, we concluded that the major
interaction of CMC7 is with oligomeric α-syn. These
results are consistent with previous studies showing
that certain polyphenolic compounds, including baica-
lein, curcumin and epigallocatechin gallate induce sol-
uble and non-toxic oligomeric formation [74].
Conclusions
From the eleven tested CMCs only two, CMC1 and
CMC7, inhibited α-syn aggregation, seeded fibril forma-
tion and toxicity in vitro. As α-syn is the main compo-
nent of Lewy bodies, which are considered the
neuropathological hallmark of PD, halting disease pro-
gression and therapeutic approaches for PD need to tar-
get α-syn spreading, aggregation and production. Our
reported compounds can be used as candidates for such
therapeutic approaches after clearly understanding their
inhibitory mechanisms of α-syn fibril formation and tox-
icity. The next interesting phase is to confirm their effect
on PD animal models. Thus, studying the following
compounds represents an important starting point for
possible examination of new molecules for future usage
as drugs for treating PD and related synucleinopathies.
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Additional file 1. α-Syn fibril formation in presence of CMCs. Incubation
of α-syn samples (25 μM) for 5 days at 37 °C with continuous shaking was
done in the presence of different concentrations of A: CMC2, B: CMC3,
C: CMC4, D: CMC5, E: CMC6, F: CMC8 and G: CMC9 (100, 50 and 25 μM).
Fibril formation was then measured by Th-T binding assay. The assays
were performed in triplicates, and the means ± standard deviations are
shown.
Additional file 2. Congo red binding for A: CMC2, B: CMC3, C: CMC4,
D: CMC5, E: CMC6, F: CMC8 and G: CMC9. α-Syn solution samples (5 μM)
either aged alone or with different molar ratios of CMCs were mixed with
a final concentration of 5 μM Congo red. By using a spectrophotometer,
the UV absorbance spectrum was recorded from 400 to 600 nm.
Additional file 3. Coomassie blue staining of SDS-PAGE of CMCs sam-
ples co-incubated with α-syn for 5 days at molar ratios (CMC: α-syn) of
4:1, 2:1 and 1:1.
Additional file 4. Effect of CMCs alone on BE(2)-M17 cells. MTT assay
was used to estimate the viability of BE(2)-M17 human cells. The results
are expressed as percentages of the average of the control (i.e., untreated
cells). The cells were treated with A: CMC1, B: CMC7, C: CMC10, and D:
CMC11 at three different concentrations (20, 10 and 5 μM) for 48 h prior
to the addition of MTT. Means ± standard deviations are from the
average of 3 wells.
Additional file 5. Effect of CMCs on the seeding of α-syn monomers
with fibrils. α-syn monomers (100 μM) were seeded with 2 μM sonicated
α-syn fibrils, incubated with or without A: CMC2, B: CMC3, C: CMC4, D:
CMC5, E: CMC6, F: CMC8 and G: CMC9, H: CMC10 and I: CMC11 at dif-
ferent concentrations (10 and 50 μM) for 6 h with continuous shaking at
37 °C. Th-T binding assay estimated fibril formation. Assays were per-
formed in triplicates (average of triplicate measurements ± standard
deviations.
Additional file 6. Effects of CMCs on α-syn aggregation in primary neur-
onal cultures. Mouse primary cultures (6div) were treated with seeds and
CMCs at (1:5 and 1:20) ratio for 72 h. In some experiments, neurons were
pre-treated with the CMCs for 24 h before addition of the seeds. Follow-
ing Triton-X extraction, synuclein species were visualized with the α-syn
antibody C20. Insoluble α-Syn species were increased following treatment
with the seeds. No changes were observed in pS129- α-syn species in
both conditions tested. GAPDH was used as a loading control. 1 CMC 10
(1:5), 2 CMC10 (1:20), 3 CMC 7 (1:5), 4 CMC 7 (1:20), 5 CMC 1 (1:5), 6
CMC1 (1:20), 7 pretreated CMC 7 (1:5), 8 pretreated CMC 7 (1:20), 9 pre-
treated CMC 1 (1:5), 10 pretreated CMC 1 (1:20), 11 neurons+ seeds, 12
untreated cells.
Additional file 7. Effects of CMC1 and CMC7 on cell viability. The cell
cytotoxicity assay was carried out on BE(2)-M17 human cells treated with
either α-syn monomers, α-syn fibrils, CMC1, or CMC7 by MTT assay. Cells
were treated with a range of concentrations (0.01–40 μM) of α-syn and
CMCs for 48 h prior to the addition of MTT. The results are expressed as
percentages of the average of the control (i.e., untreated cells). Means ±
standard deviations are from the average of 3 wells.
Additional file 8. Size Exclusion Chromatography. A. Gel-filtration profile
of MW standard containing Ferritin 440 KDa, Aldolase 171 KDa, Abmumin
68 KDa and Chymotrypsinogen A 25 KDa using Superdex 200 column at
0.1 ml/min flow rate (0.5 ml/fraction). B. Gel-filtration profile for mono-
meric α-syn using Superdex 200 column at 0.1 ml/min flow rate (0.5 ml/
fraction).
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